New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Merrimack Pharmaceuticals, Inc.
MACK
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

224M

Biotechnology

15.14USD

Shape0.01 ( 0.10%)
Market Closed (as of May 17, 19:59 EDT)
favorite-chart

Relative Strenght

100
favorite-chart

Volume Buzz

405%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

5%
OverviewChart

Quote Panel

Shape
Updated March 23, 2025
1W % 1M % 3M % 1Y 51702.65 %

Key Metrics

Shape

  • Market Cap

    223.97M

  • Shares Outstanding

    14.79M

  • Share in Float

    9.66M

  • Dividende

    15.1

  • Earning Date

    No Data

  • Price Target

    15.145

  • Average Volume

    182633

  • Beta

    1.416

  • Range

    11.53-15.89

  • Industry

    Biotechnology

  • Website

    https://www.merrimack.com

  • Sector

    Healthcare

Fundamentals

Shape

Relative Strength

Shape

MACK

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

No Data Available

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Shape

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

No Data Available

Earnings GrowthShape

status-upYoY

Current

Estimates

Q2.22

arrow
arrow

N/A

-0.04
vs -0.06

Q3.22

arrow
arrow

N/A

-0.03
vs -0.04

Q4.22

arrow
arrow

N/A

-0.03
vs -0.03

Q1.23

arrow
arrow

N/A

-0.02
vs -0.04

Q2.23

arrow
arrow

N/A

-0.03
vs -0.04

Q3.23

arrow
arrow

N/A

-0.02
vs -0.03

Q4.23

arrow
arrow

N/A

-0.01
vs -0.03

Q1.24

arrow
arrow

N/A

-0.03
vs -0.02

Q3.24

arrow
arrow

+6813%

1.34
vs -0.02

Q4.24

arrow
arrow

+15514%

1.54
vs -0.01

Sales GrowthShape

status-upYoY

Current

Estimates

Q4.21

arrow
arrow

NA

NA  vs NA

Q1.22

arrow
arrow

NA

NA  vs NA

Q2.22

arrow
arrow

NA

NA  vs NA

Q3.22

arrow
arrow

NA

NA  vs NA

Q4.22

arrow
arrow

NA

-445000.00  vs NA

Q1.23

arrow
arrow

NA

NA  vs NA

Q2.23

arrow
arrow

NA

NA  vs NA

Q3.23

arrow
arrow

NA

NA  vs NA

Q4.23

arrow
arrow

+100%

NA  vs -445000

Q1.24

arrow
arrow

NA

NA  vs NA

Return on EquityShape

status-upQoQ

Q2.22

arrow
arrow

-3%

-0.03
vs -0.01

Q3.22

arrow
arrow

-2%

-0.02
vs -0.03

Q4.22

arrow
arrow

-3%

-0.03
vs -0.02

Q1.23

arrow
arrow

0%

-0.00
vs -0.03

Q2.23

arrow
arrow

-2%

-0.02
vs -0.00

Q3.23

arrow
arrow

-1%

-0.01
vs -0.02

Q4.23

arrow
arrow

-1%

-0.01
vs -0.01

Q1.24

arrow
arrow

-11%

-0.11
vs -0.01

Institutionnal OwnershipShape

status-upQoQ

Q4.22

arrow
arrow

53

53
vs 42

26%

Q1.23

arrow
arrow

55

55
vs 53

4%

Q2.23

arrow
arrow

66

66
vs 55

20%

Q3.23

arrow
arrow

69

69
vs 66

5%

Q4.23

arrow
arrow

73

73
vs 69

6%

Q1.24

arrow
arrow

71

71
vs 73

-3%

Q2.24

arrow
arrow

6

6
vs 71

-92%

Q4.24

arrow
arrow

1

1
vs NA

NA

Earnings Growth

Latest News

MACK

businesswire.com

16 hours ago

Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
MACK

businesswire.com

16 hours ago

Merrimack Receives $225 Million Milestone Payment from Ipsen
MACK

businesswire.com

16 hours ago

Merrimack Reports Full Year 2023 Financial Results
MACK

businesswire.com

16 hours ago

Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
MACK

businesswire.com

16 hours ago

Merrimack Reports Third Quarter 2023 Financial Results
MACK

businesswire.com

17 hours ago

Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution